A Phase II Study of continuous, low-dose LBH 589 (Panobinostat) in Patients with Refractory Solid Tumors, including CNS tumors [ 2017 - 2021 ]

Research Grant

Researchers: Dr Jayesh Desai (Principal investigator) ,  Prof David Ashley (Principal investigator) ,  Dr Jason Cain ,  Dr Nicholas Gottardo ,  Dr Paul Wood

Brief description Research done recently across three separate Australian laboratories has shown great promise with a new anti-cancer drug LBH589 used for cancers in children and young adults. We wish to start a clinical trial of LBH589 in children and young adult patients with cancer.

Funding Amount $AUD 830,155.09

Funding Scheme Project Grants

Notes Standard Project Grant